Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
10
Drugs by Therapeutic Interaction Recommendation
Area Geometric mean change concerning co-
(%) administration
(Possible mechanism)
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant
use of lamivudine with
In vitro lamivudine inhibits the cladribine is not
intracellular phosphorylation of recommended (see section
cladribine leading to a potential 4.4).
risk of cladribine loss of efficacy
in case of combination in the
clinical setting. Some clinical
findings also support a possible
interaction between lamivudine
and cladribine.
OPIOIDS
Methadone/Abacavir Abacavir: AUC As only limited data are
(40 to 90 mg once daily for 14 Cmax 35% available the clinical
days/600 mg single dose, then significance is not known.
600 mg twice daily for 14 Methadone: CL/F 22% Monitor for signs of
days) zidovudine toxicity (see
Methadone/Lamivudine Interaction not studied. section 4.8).
Methadone/Zidovudine Zidovudine AUC 43%
(30 to 90 mg once Methadone AUC Methadone dosage adjustment
daily/200 mg every 4 hours) unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
RETINOIDS
Retinoid compounds Interaction not studied. Insufficient data to
(e.g. isotretinoin)/Abacavir recommend dosage
Possible interaction given adjustment.
common pathway of elimination
via alcohol dehydrogenase.
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Lamivudine
No drug interaction studies
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Zidovudine
URICOSURIC
Probenecid/Abacavir Interaction not studied. As only limited data are
Probenecid/Lamivudine Interaction not studied. available the clinical
Probenecid/Zidovudine Zidovudine AUC 106% significance is not known.
(500 mg four times Monitor for signs of
daily/2 mg/kg thrice daily) (UGT inhibition) zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Ethanol/Abacavir Abacavir: AUC 41% No dosage adjustment
(0.7 g/kg single dose/600 mg Ethanol: AUC necessary.
single dose)
(Inhibition of alcohol
dehydrogenase)
Ethanol/Lamivudine Interaction not studied.
Ethanol/Zidovudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RETINOIDS
Retinoid compounds Interaction not studied. Insufficient data to
(e.g. isotretinoin)/Abacavir recommend dosage
Possible interaction given adjustment.
common pathway of elimination
via alcohol dehydrogenase.
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Lamivudine
No drug interaction studies
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
12
phosphorylation of
cladribine leading to a
potential risk of cladribine
loss of efficacy in case of
combination in the
clinical setting. Some
clinical findings also
support a possible
interaction between
lamivudine and cladribine
Opioids
Methadone/Abacavir Abacavir: Methadone dose adjustment likely not
(40 to 90mg once daily for 14 AUC ↔ needed in majority of patients;
days/600mg single dose, then Cmax ↓35% occasionally methadone re-titration may
600mg twice daily for 14 days) be required.
Methadone:
CL/F ↑22%
Retinoids
Retinoid compounds Interaction not studied Insufficient data to recommend dose
(e.g. Isotretinoin) adjustment.
Possible interaction given
common pathway of
elimination via alcohol
dehydrogenase (abacavir-
component).
Miscellaneous
Alcohol
Ethanol/Dolutegravir Interaction not studied No dose adjustment necessary.
Ethanol/Lamivudine (Inhibition of alcohol
dehydrogenase)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
49
Retinoids
Retinoid compounds Interaction not studied Insufficient data to recommend dose
(e.g. Isotretinoin) adjustment.
Possible interaction given
common pathway of
elimination via alcohol
dehydrogenase (abacavir-
component).
Miscellaneous
Alcohol
Ethanol/Dolutegravir Interaction not studied No dose adjustment necessary.
Ethanol/Lamivudine (Inhibition of alcohol
dehydrogenase)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 46098324b732f0796c2c1ff7a0150fc44061ae77d4a4241df738cc3536fecdfa · Zeichen 18142–18846 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.